ERBB2 and breast carcinoma: This combination is frequently used in HER2-positive breast cancer, a subtype of breast cancer with amplification or overexpression of the human epidermal growth factor receptor 2 (HER2) oncogene, which represents approximately 15% of all breast cancers [7, 8].